References
- Margel D, Tal R, Baniel J. Serum tumor markers may predict overall and disease specific survival in patients with clinically organ confined invasive bladder cancer. J. Urol.178(6), 2297–2300 (2007).
- Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J. Urol.163(6), 1693–1696 (2000).
- Buy JN, Moss AA, Guinet C et al. MR staging of bladder carcinoma: correlation with pathologic findings. Radiology169(3), 695–700 (1988).
- Shariat SF, Palapattu GS, Karakiewicz PI et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur. Urol.51(1), 137–151 (2007).
- Cook AM, Huddart RA, Jay G, Norman A, Dearnaley DP, Horwich A. The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer. Br. J. Cancer82(12), 1952–1957 (2000).
- Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J. Biol. Chem.276(29), 27371–27375 (2001).
- Chang A, Cai J, Miranda G, Groshen S, Skinner D, Stein JP. Usefulness of CA 125 as a preoperative prognostic marker for transitional cell carcinoma of the bladder. J. Urol.172, 2182–2186 (2004).
- Ammon A, Weber MH, Wallner I et al. Expression of the tumor-associated glycoproteins MCA, CA 125 and BW 495/36-P in epithelial tumors of the kidney and the urinary bladder. Int. J. Biol. Markers9(4), 224–230 (1994).
- Berek JS, Bast RC Jr. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer76, 2092–2096 (1995).
- Bast RC Jr. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol.21, 200–205 (2003).
- Izes JK, Dyer MW, Callum MG, Bankes P, Libertino JA, Caffrey JA. CA 125 as a marker of tumor activity in advanced urothelial malignancy. J. Urol.165, 1908–1913 (2001).
- Chung HH, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer. Acta Obstet. Gynecol. Scand.85(12), 1501–1505 (2006).
- Chaube A, Tewari M, Singh U, Shukla HS. CA 125: a potential tumor marker for gallbladder cancer. J. Surg. Oncol.93(8), 665–669 (2006).
- Kouba EJ, Lentz A, Wallen EM, Pruthi RS. Clinical use of serum CA-125 levels in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. Urol. Oncol.27(5), 486–490 (2009).
- van Ingen HE, Chan DW, Hubl W et al. Analytical and clinical evaluation of an electro-chemiluminescence immunoassay for the determination of CA 125. Clin. Chem.44(12), 2530–2536 (1998).
- Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am. J. Clin. Pathol.117(3), 471–477 (2002).